Related Experiment Video
Updated: Aug 9, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Advances in the management of metastatic androgen-independent prostate cancer
Damian A Laber1, Kloecker Goetz H, Leela Bhupalam
1Division of Hematology and Medical Oncology, University of Louisville, J G Brown Cancer Center, KY 40202, USA. damianla@ulh.org
Abstract:
Over the last century, advances in the management of men with metastatic androgen-independent prostate cancer (AIPC), the type of prostate cancer that has continued to grow after androgen withdrawal or castration, have been slow. Patients with metastatic AIPC usually undergo a cascade of palliative radiation therapy and chemotherapy with modest impact on their inevitable deterioration and death. Currently, there is no therapy capable of achieving a cure for men with AIPC. In the past, chemotherapy was only used for symptomatic patients. Recently there has been a paradigm shift after two landmark studies demonstrated an improvement in survival for men with AIPC treated with docetaxel-based chemotherapy. This review focuses on the management principles and systemic chemotherapy options against AIPC. A good understanding of the prognosis, treatment options and scientific advances is of utmost importance for the physician advising men suffering from AIPC. Research to improve survival and quality of life for our patients should be strongly supported.
Insights
Advances in managing metastatic androgen-independent prostate cancer (AIPC) have been slow. Recent chemotherapy improvements offer survival benefits, but cures remain elusive for this prostate cancer type.
Area of Science:
- Oncology
- Urology
Background:
- Metastatic androgen-independent prostate cancer (AIPC) management has seen limited progress over the past century.
- Current treatments, including palliative radiation and chemotherapy, offer modest benefits and no cure for AIPC.
- A paradigm shift is occurring with recent findings on chemotherapy's impact on survival.
Purpose of the Study:
- To review current management principles for AIPC.
- To discuss systemic chemotherapy options for AIPC.
- To highlight the importance of understanding prognosis and scientific advances in AIPC treatment.
Main Methods:
- This is a review article.
- Focuses on summarizing existing literature on AIPC management and chemotherapy.
- Synthesizes information on prognosis, treatment options, and recent scientific advances.
Main Results:
- Chemotherapy, particularly docetaxel-based regimens, has demonstrated improved survival in AIPC patients.
- Despite advances, a cure for metastatic AIPC is not yet available.
- Understanding treatment options and prognosis is crucial for patient care.
Conclusions:
- Systemic chemotherapy represents a significant advance in AIPC management, improving survival.
- Continued research is essential to enhance survival and quality of life for AIPC patients.
- Physicians need a comprehensive understanding of AIPC to effectively advise patients.
